Aspira Women's Health Inc. · OTC:AWHL

Aspira Women's Health — Vermillion — Proxy Contest (February 2013)

40 slides from Aspira Women's Health's proxy contest presentation, Feb 21, 2013

  1. Slide 1: Vermillion, Inc. Schedule 14A

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ ¨ Check the appropriate box: ¨ Pre

  2. Slide 2: Filing Party and Date Filed

    (3) Filing Party: (4) Date Filed:

  3. Slide 3: ISS Presentation, February 21, 2013

    ISS Presentation February 21, 2013

  4. Slide 4: Forward-Looking Statements

    Forward-Looking The “may,” intentions. introduced and actual Should This expected. 1All logos, are following presentation results, “are one subject trademarks Such by or expected performance the more information tostatements is company certain Statements copyright ofto,” and these risks, “will,” bra

  5. Slide 5: Executive Summary

    EXECUTIVE SUMMARY

  6. Slide 6: Corporate Vision

    Corporate 3To becomeVision a recognized leader in the advancement of women’s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases

  7. Slide 7: Who We Are

    Who As In OVA1 Our 42. Proteomics collaboration an flagship expanding we industry represents are…product, isleader patent with the a new large-scale prestigious in OVA1®, portfolio class Proteomics2, ofis helps study software-based research the first sustain of weproteins, discover institutions, FDA

  8. Slide 8: Unique, Proven, Industry-Leading Strengths

    Unique Proven Industry-Leading >10-yr “Gordian Innovation Renowned OVA1® Ability Result: Outsourced/Flexible Core Clinical, 5Enables collaborations alliance Strengths to IP, Translational rapid “firsts” QA, knot” leverage papers, Clinical includes RA, response with approach open Offer Discovery FDA

  9. Slide 9: Renowned Partnerships and Expected Milestones

    Renowned Potential Post-surgical Dr. Presurgical 6(1) Estimated. Fred Coleman John Rob Ueland Martignetti collaborator Clinical diagnosis monitoring, Expected (U(M.D. Partnerships Kentucky) (Mt. & fortriage milestones Anderson) OvaDx Sinai, prognosis of –NYC) Set OVA1® endometrial – aid –are the ICS

  10. Slide 10: Diagnostic Patent Portfolio

    #Diagnostic Disease Families Ovarian PAD Alzheimer’s Breast Other TOTAL 710ofnew Patent 43cancer 5patents 2Area 31 cancer 1U.S. - Patents Patent 15disease 4Non-U.S. 7granted 17 1 -Portfolio 4Issued 34 3or 2 /allowed Allowedsince January 2011 7 new biomarker patent families acquired from Correlogic

  11. Slide 11: Ovarian Cancer Franchise / OVA1

    OVARIAN CANCER FRANCHISE / OVA1®

  12. Slide 12: Ovarian Cancer: Unmet Clinical Need

    OVA1 Lifetime -Ovarian Only 5-year 3. Key Mass Adnexal % Cases IStage II III 9IV This More 22,000 Only 24% 6% Surveillance, of 55% 15% to 5-year 165% Rate relates 95% Addresses survival 19% Survival: than in15-30% 0-20% cancer determined risk 3 women are Survival 1of to million rates is diagnosed >1

  13. Slide 13: Limitations of Traditional Approaches to Diagnosis

    What’s CA125 Before Misleading: Transvaginal Unreliable: Variable: Physical Limited 100,000 50,000 35,000 ~1,000 Just 10 1,000 OVA1, General OB/GYNS GOs the Blood #Family exam Results of Gynecologic Problem 50% evaluation Elevated Gynecologic Ultrasound/Imaging Test CA125 not Surgeons Practitioners

  14. Slide 14: The OVA1 Solution

    The OVA1 while test”) a“As Society 4. 5. 11gynecologic Ueland http://www.sgo.org/newsroom/position-statements-2/ova1/ Solution: physicians and 95% isofan represents FR, Gynecologic negative FDA-cleared OVA1® oncologist DeSimone who predictive are a new Oncology, expert is CP, blood class indicated.”

  15. Slide 15: How OVA1 Is Used

    How -“Using Society Lower Treated Higher Specialist 12 Dr. Beth OVA1 Probability Probability OVA1 of byInvolved Y. Gynecologic OB/GYN isKarlan, to Typically better of of2005 Malignancy Malignancy triage Oncology Used: President, women The OVA1® with a Diagnostic pelvic massPathway may lead to improv

  16. Slide 16: Validated Study Results

    Validated >1,000 Study Total: 4. 6. 7. 13 Ueland Miller R.E.44 2Bristow 1adnexal sites: sites &R, Through FR, 2 Smith sites: :17 DeSimone 17surgeries et al. 10 A, 44/DeSimone Clinical Gynecologic >250 CP, Seamon Sites4,6,7 various C, et Oncology al. LG, malignancies Obstet et al.128 Gynecol. Obstet

  17. Slide 17: OVA500 Multi-Center Study

    OVA1®: OVA500 Outstanding >1,000 Overall Confirms Gynecologic Principal “Thanks determinants Dr. 7. 14 R.E. Robert Bristow patients both to KEY OVA500 Investigator the E. diagnostic performance studies Oncology of unrivaled Bristow TAKEAWAYS in et survival.” al. combined Multi-Center identified /for

  18. Slide 18: OVA500 Combined Performance Results

    OVA1®: New OVA500 Combined Sensitivity Physician Overall Premenopausal Population 94% Early 91% Cancer 7. 15 R.E. 91% OVA500 Stage Bristow (Stage 96% Multi-Center OVA500 Assessment w/ NPV Premenopausal Ovarian 98% Risk Imulti-site Early et & Overall al. II) Multi-Center Stratification Premenopausal

  19. Slide 19: OVA1 vs ROMA Performance

    Stand ROMA OVA1 4. 8. 16 Ueland ROMA® Alone (n=) maintains (n=) FR, 39/40 (HE4 Performance Sensitivity 9/12 DeSimone a34/34 52/52 EIA high+level of 26/38 57/68 Architect CP, OVA14 of Seamon 71/86 149/161 sensitivity CA125 & ROMA8 LG, II™) et across al. Instructions Obstet a broad Gynecol. range Foro

  20. Slide 20: Expanding OVA1 Payer Coverage

    OVA1 27 47 Medicare (BCBS) 45 Department Advantage Other 1.5 with Total Highmark BCBS (Millions 36M 41M 47M47M Q2 5M 10M 21M 30M 2010 17 Blue million Q3 million Quest 36M 2011 Lives 94.9 payors Expanding Coverage Q4 Cross of /36M million of Q1 2012 Medicare Diagnostics Currently of Lives) Medicare c

  21. Slide 21: New CPT Code Effective January 2013

    Newuse AMA accelerates CMS will CPT® They 18 AMA provides (Centers assigned (Current “gap-fill” CPT expanding uniform for aProcedural Code unique Medicare process –coverage language aCategory Watershed toTerminology) &determine Medicaid and that 1 CPT adoption Industry accurately CPT Services) Code

  22. Slide 22: OVA1 Growth and Clinical Success

    OVA1 Nearly coverage Growth 2013 Performed 9. 20 Guidance Clinical 38K indecisions, OVA1 Since tests issued &FDA ordered Tests Commercial and i.e.,Clearance effective Medicare through Success only 2012 andon Blue Demonstrates >5,371 11-12-2012 Cross ordering BlueStrong Shield physicians Growth Posit

  23. Slide 23: Expanding Indications and Product Roadmap

    Expand extension Ovarian U.S. Indication Triage Adnexal High Drug Monitoring & TBD 10. 21 Prediction Approximate Target Risk Selection 300k OVA1 Cancer Market Masses for Testpresurgical use Population10 Roadmap Opportunity Xestimates, to 1 Million include monitoring based risk assessment on Vermilli

  24. Slide 24: Vascular Medicine Program / Peripheral Artery Disease

    VASCULAR MEDICINE PROGRAM / PERIPHERAL ARTERY DISEASE 23

  25. Slide 25: PAD Prevalence and Market Opportunity

    PAD Prevalence Obese Early Currently “In (1) At U.S. Diabetics (Millions) Smokers Elderly (Less TOTAL 24 Risk Steg the Market diagnosis Overlap) people next aged Group(3) 59.3 etaged aged no al, offive Opportunity 65+ blood JAMA, aged PAD 50+ 50+ (11.5) and years, 38.0 Population 19.6 50+ test is 13

  26. Slide 26: PAD Initial Study Results

    Positive PAD 1,025 Identified Results Publication Study Society “…Results 25 intended subjects results recently for Initial PAD indicate Vascular would were use were Study inpresented 17 study: further presented this studied Medicine of Results 20 biomarker build at (85%) byan at for 2012 researcher

  27. Slide 27: Seeking a Development Partner for PAD

    Seeking A Additional 26significant Development product marketdevelopment opportunity Partner forand exists Peripheral clinical Extensive Artery trial work intended Disease is required use (PAD) study This completed is the best Requires avenue cardiology to realize value market forsegment our PADexpe

  28. Slide 28: Management Team

    MANAGEMENT TEAM 27

  29. Slide 29: Management Team Experience

    Management Deep Title Hybritech, Bruce Molecular Beckman Senior Donald Business Munroe, Capitol Biopharmaceuticals William Abbott Chief Eric Officer 28 Schoen Experience management Accounting Scientific A. Vice Diagnostics Alticast, Vial, G. B. Ph.D. Huebner Development Coulter, Diagnostics (Microar

  30. Slide 30: Board of Directors

    BOARD OF DIRECTORS 29

  31. Slide 31: Board of Directors Experience

    BoardTherapeutics, Established development Title James Hybritech, Bruce Philadelphia Diagnostics John Financial Pain Peter Laboratories, Carl William Severinghaus Wallen, Director 30 Experience F. S. A. of S.Hamilton Ph.D. Roddy C. Tecan Burns Directors Huebner Officers Gen-Probe, IDEXX Board Nation

  32. Slide 32: Board Committees

    Board J. Chairman Audit Governance Compensation Business Interim *Committee 31 Burns Committee Committees CEO W. Dev 9 Wallen, Cmte Chairman 9Cmte Cmte 99 9*99 PhD. 99* 99* 9 C. Severinghaus P. Roddy B. Huebner

  33. Slide 33: Board Qualifications Matrix

    Board Age Industry J. B. W. P. C. Robin Robert 32 Burns Roddy Huebner Severinghaus Wallen, Healthcare Vedova Qualifications Goggin 66 &53Sales PhD. 962 99 959 99 48 9Board 60 69 Mgmt 999 99999 9/9Experience 9Finance 9999 9 Marketing Int’l R&D General Comp

  34. Slide 34: New Board Nominee Robert Goggin

    NewBoard Robert Mr. No 33 medical experience Goggin’s Board S. Goggin Audit Governance Compensation experience Nominee reimbursement lack inCommittee with managing ofFDA Qualifications: ofexperience any committee submissions experience or experience kind operating experience or acompliance Healthcar

  35. Slide 35: History of Mr. Goggin's Board Seat Request

    History The In court We of Mr. This 34 2011, June $500,000. offered Goggin’s Goggin Court Proxy filings. 2012, of Mr. of interaction contest aand toGoggin Unacceptable Case Board the History The accept his Chancery Group was isGroup Seat filed Mr. awith dismissed wasteful to Novak Bessenyei filed su

  36. Slide 36: New Board Nominee: Elect Robin Dellaveдова

    New Board Elect Robin related Pertinent 35 Roberta has to international our the Nominee industry L. following (Robin) Knowledge market industry Dellaexperience Vedova credentials of “how to Adding fill to” tothe manage beopen aawoman productive Board a start toofthe upcontributing Directors laborato

  37. Slide 37: Approve Stock Incentive Plan Share Increase

    Stockfor Approve Used versus cash 36 to Incentive cash attract athe company Without increase the Plan best of additional ofour possible 1,300,000 size shares newauthorized management it will beshares difficult and employees to impossible – in to particular competeour forCEO talentposition over compe

  38. Slide 38: Approve Compensation

    Approve Compensation Vermillion annual 37 compensation Annual routinely Compensation retains for 2013 outside at $252,000 professional plus acompensation $50,000 bonusexperts package to evaluate and 100,000 employee stock options compensation is well versus below industry standards Vermillion Our ma

  39. Slide 39: Key Takeaways

    Key Vermillion Experienced -Success Broad 38 Nearly 5,371 Strengthening NewTakeaways patent CPT OVA500 ordering with 38K iscode, Board portfolio first an tests trends study emerging physicians effective commercial ordered andconfirms supports inManagement OVA1 industry through January to date produc

  40. Slide 40: Contact Information

    Contact TX Corporate Vermillion, Austin, 39 Information Headquarters 78738 Inc. Interim bhuebner@vermillion.com CEO Bruce12117 A. Huebner Bee CavesTel: Rd.(512) Vermillion, 519.0400 Inc.Fax: Building (512) 439.6980 3, Suite 100 www.vermillion.com 512-519-0422

Vermillion — Proxy Contest (February 2013) on 6ix